- Home
- TGNA vs PTGX Comparison
TGNA vs PTGX Comparison
Compare TGNA & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGNA
- PTGX
- Stock Information
- Founded
- TGNA 1906
- PTGX 2006
- Country
- TGNA United States
- PTGX United States
- Employees
- TGNA N/A
- PTGX N/A
- Industry
- TGNA Broadcasting
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- TGNA Industrials
- PTGX Health Care
- Exchange
- TGNA Nasdaq
- PTGX Nasdaq
- Market Cap
- TGNA 2.8B
- PTGX 2.4B
- IPO Year
- TGNA N/A
- PTGX 2016
- Fundamental
- Price
- TGNA $18.97
- PTGX $48.20
- Analyst Decision
- TGNA Strong Buy
- PTGX Strong Buy
- Analyst Count
- TGNA 4
- PTGX 8
- Target Price
- TGNA $21.75
- PTGX $66.50
- AVG Volume (30 Days)
- TGNA 2.1M
- PTGX 1.5M
- Earning Date
- TGNA 05-08-2025
- PTGX 05-06-2025
- Dividend Yield
- TGNA 2.63%
- PTGX N/A
- EPS Growth
- TGNA 54.83
- PTGX N/A
- EPS
- TGNA 3.53
- PTGX 4.23
- Revenue
- TGNA $3,101,971,000.00
- PTGX $434,433,000.00
- Revenue This Year
- TGNA N/A
- PTGX N/A
- Revenue Next Year
- TGNA $11.77
- PTGX $8.12
- P/E Ratio
- TGNA $5.34
- PTGX $11.40
- Revenue Growth
- TGNA 6.56
- PTGX 624.05
- 52 Week Low
- TGNA $12.35
- PTGX $24.22
- 52 Week High
- TGNA $19.62
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- TGNA 60.42
- PTGX 51.16
- Support Level
- TGNA $18.27
- PTGX $51.06
- Resistance Level
- TGNA $19.13
- PTGX $53.70
- Average True Range (ATR)
- TGNA 0.46
- PTGX 2.05
- MACD
- TGNA 0.04
- PTGX -1.08
- Stochastic Oscillator
- TGNA 91.40
- PTGX 20.16
About TGNA TEGNA Inc
Tegna Inc is a media company with a portfolio of broadcast stations and digital sites. The firm has television stations and radio stations in approximately U.S. markets. The company owns multicast networks of True Crime Network, Twist, and Quest. Each television station also has a robust digital presence across online, mobile, connected television, and social platforms, reaching consumers on all devices and platforms used to consume news content. It generates key revenue from advertising and marketing services, subscriptions, political advertising, and other services.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.